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Background. Artemisinin combination therapy is recommended as treatment for uncomplicated Plasmodium
falciparum (Pf ) malaria, whereas chloroquine is still widely used for non-Pf infections. A common treatment for
both vivax and falciparum malaria would be welcome.
Methods. A longitudinal prospective effectiveness study of 1682 children aged 3–27 months in outpatient
clinics in Papua New Guinea. The main outcome was clinical treatment failure rate following treatment with
artemether/lumefantrine (AL).
Results. Among 5670 febrile episodes, 1682 (28%) had positive rapid diagnostic test (RDT) results and were
treated with AL. A total of 1261 (22%) had an infection conﬁrmed by blood slide examination. Of these, 594 Pv
and 332 Pf clinical malaria cases were included in the primary effectiveness analysis. Clinical treatment failure
rates at 7, 28, and 42 days were 0.2%, 2.2%, and 12.0%, respectively, for Pv and 0.3%, 1.2%, and 3.6%, respectively,
for Pf. A single malaria-unrelated death occurred within 42 days following treatment with AL, in a child who was
aparasitemic by blood slide at reattendance.
Conclusions. AL provides a rapid clinical response against both Pf and Pv malaria, but is associated with a
high rate of Pv recurrent clinical episodes between days 28 and 42. In order to prevent relapsing infections from
long-lasting hypnozoites, AL should ideally be complemented with a course of primaquine. In the absence of
better treatment and diagnostic options, the use of AL in young children in routine practice is an acceptable,
interim option in coendemic areas where Pv is resistant to chloroquine and speciﬁc treatment for Pv hypnozoites
not feasible.
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Whereas artemisinin combination therapies (ACTs)
are now almost universally recommended as ﬁrst-line
treatment for uncomplicated Plasmodium falciparum
(Pf ) malaria [1], chloroquine (CQ) is still recommend-
ed for non-Pf infections in most countries. The differ-
ing recommendations for Pf and Pv malaria have
several potential negative consequences in routine
clinical practice. Most importantly, they require good-
quality parasitological diagnosis in remote areas where
most malaria cases are diagnosed and treated. Even
where species diagnosis is performed, misdiagnoses
occur, and minority species in a mixed infection can
easily be missed. Given the almost universal presence
of CQ-resistant Pf [2–4], such misdiagnosis can have
serious consequences. Using rapid diagnostic tests
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(RDTs) based on Pf histidine-rich protein 2/pan–lactate dehy-
drogenase, or Pf-HRP2/aldolase, it is impossible to differenti-
ate monospecies Pf infections from mixed infection with Pf
and another species in the absence of microscopic conﬁrma-
tion. The resulting complex recommendations are likely to
confuse health workers in coendemic areas. Finally, in areas
with signiﬁcant levels of CQ resistance such as Oceania and
Indonesia, but also increasingly elsewhere [5], the World
Health Organization now recommends the use of ACTs also
for the treatment of Pv [1]. Thus, a common treatment ap-
proach for both vivax and falciparum malaria would be
welcome.
Douglas and colleagues [6] reviewed the appropriateness of
a single ACT-based strategy for both Pf and Pv in coendemic
regions and concluded that it might be a reasonable option
where Pv is resistant to chloroquine. However, the authors
also pointed out that this recommendation is based on a small
number of highly controlled efﬁcacy trials and that data are
lacking on the effectiveness of this strategy in routine set-
tings [7–9].
Papua New Guinea (PNG), Solomon Islands, and Vanuatu
have adopted artemether/lumefantrine (AL) as a common
ﬁrst-line antimalarial treatment. To date, 3 trials have investi-
gated the in vivo efﬁcacy of AL for Pv in endemic populations
[4, 10, 11]. Despite good initial clearance of parasites, clinical
recurrences occurred in >10% of recipients within 42 days.
Karunajeewa et al [4] showed also in PNG that more than half
of patients with Pv infections at enrollment had recurrent Pv
parasitemia by day 42 following initial treatment with AL. All
these trials were carried out in highly controlled settings with
active case detection, and a recent review by Bassat [12] con-
cluded, like Douglas [6], that a rigorous assessment of the use
of AL in routine clinics to treat Pv infections is required.
Papua New Guinea is highly endemic for malaria in coastal
areas, where malaria incidence rates in small children are ap-
proximately 1 episode per year per child [7, 9]. In children
aged <2 years, Pv accounts for at least half of all malaria infec-
tions and clinical episodes [7, 9, 13]. As part of a large trial of
intermittent preventive treatment in infancy (IPTi) [9], all
malaria participants were treated with a 3-day course of AL
irrespective of infecting species. This standardized treatment
strategy offered a unique opportunity to assess the effective-
ness of a common treatment with AL for malaria in young
children based on RDT results in routine clinics.
METHODS
Context and Study Sites
This work was carried out from 2006 to 2010 alongside a 3-
arm drug trial of IPTi including 1605 children aged 3–27
months (www.clinicaltrials.gov: NCT00285662) [9]. Children
were randomly assigned to a treatment course of sulfadoxine/
pyrimethamine (single dose, 25/1.25 mg/kg) combined with 3
days of either 10 mg/kg of amodiaquine or 4 mg/kg of artesu-
nate, or to a placebo group. The treatments were given every 3
months during the ﬁrst year of life. This trial took place in 2
different settings: Mugil (Madang province), the main study
site, at which 1125 study participants were enrolled, is situated
60 km north of Madang town. It is a rural area with an inci-
dence rate of clinical malaria of 0.94 episodes per child per
year, with Pv accounting for two-thirds of all infections [9].
Maprik (East Sepik province), 400 km north of Madang, was a
secondary study site where 480 study participants were en-
rolled. The incidence rate of malaria is 0.13 episodes/child/
year, with Pf accounting for two-thirds of all episodes [9].
Data Collection (Passive Case Surveillance)
A passive case detection surveillance system was set up along-
side the IPTi study to collect data on illness episodes as well
as to monitor potential adverse events related to study drugs.
A standard case report form was ﬁlled that included relevant
signs and symptoms as well as details of the clinical manage-
ment. When presenting with fever or history of fever in the
past 48 hours, children were screened with an RDT for Pf and
non-Pf malaria infections (ICT Combo, South Africa) and
only treated with AL (Coartem, Novartis, Switzerland) if the
test result was positive. Treatment doses of AL were adapted
according to body weight of the children. The ﬁrst dose was
given directly by the nurses (squeezed with water) and the
subsequent doses were provided to parents with instructions.
At the time of the study, a course of primaquine for radical
cure of Pv hypnozoites was not part of the PNG standard
treatment guidelines. In case of symptoms or signs of severe
disease, children were admitted to the nearest health facility.
Two thick and thin blood slides (BSs) for malaria microscopy
were collected. Parents could also present at mobile clinics
that visited participating villages on a monthly basis to deliver
the IPTi intervention.
Further details of the clinical trial and the morbidity sur-
veillance used have been reported previously [9]. Ethical ap-
proval for the IPTi study was granted by the Medical Research
Advisory Committee of PNG (MRAC number 05/20).
Study Design and Procedures
Febrile episodes were identiﬁed in the IPTi morbidity database
according to the following criteria: illness episodes that oc-
curred in children aged 3–27 months with history of fever
and/or axillary temperature >37.5° without records of a posi-
tive RDT for malaria in the past 4 weeks, without fever in the
past 2 weeks, and without a severe illness. A clinical malaria
case was deﬁned as a febrile episode with a positive RDT that
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was treated with AL. An individual child could contribute 1 or
more illness episodes to the analyses.
The clinical effectiveness of treating young children for
malaria with a common treatment of AL based on RDT
results was investigated in the following way: Clinical treat-
ment failures were deﬁned as patients who spontaneously reat-
tended the clinic with a febrile illness and a BS-conﬁrmed
infection with the same species within a maximum of 42 days.
Only the clinical malaria episodes with an infection conﬁrmed
by both RDT and BS results at the initial visit were retained.
Mixed infections (RDT and BS positive for Pf and Pv) were
excluded from the analysis. Patients were censored when they
reattended within the observation period with a heterologous
recurrence (eg, Pv following a Pf infection) and received
malaria treatment. For all analyses, children who had received
an IPTi treatment dose within 42 days following the initial
clinical episode were excluded.
All children with a positive RDT were included in an analy-
sis investigating their clinical response within 28 days follow-
ing routine management with AL of clinical malaria based,
irrespective of the BS result. For this analysis, we excluded all
episodes that received an IPTi dose before day 28. On reat-
tendance, we looked whether they still had fever, and exam-
ined the clinical and parasitological outcomes (RDT and/or
BS). These were classiﬁed as severe illness (including death) or
nonsevere illness treated as ambulatory cases. Any illness
episode was deﬁned as severe if it resulted in hospital admis-
sion or was life-threatening.
Interpretation of BS and RDT Results
Thick ﬁlms were examined by light microscopy for 200 ﬁelds,
and parasite species and densities for positive cases were re-
corded as the number of parasites per 200 white blood cells.
Densities were converted to the number of parasites per mi-
croliter of blood assuming 8 000 cells/μL. All slides were read
independently by 2 experienced microscopists; in cases of dis-
crepant readings, a third independent read was performed.
The interpretation of the combination of BS and RDT was
done according to a matrix published elsewhere (Supplemen-
tary Table 1) [14]. The malaria status was deﬁned as (1)
negative = BS and RDT negative, BS or RDT negative, and cor-
responding BS or RDT absent; (2) deﬁnite malaria = BS and
RDT positive; (3) probable malaria = BS positive and RDT
negative or absent; or (4) possible malaria = RDT positive and
BS negative or absent.
Data Analysis
All data management and analyses were performed using
Stata software (versions 11.0 and 12.0). The analysis was strat-
iﬁed by species (Pf or Pv), excluding mixed infections. Survival
analysis was performed using a Cox proportional hazards
model to assess hazard ratios (HRs) for the difference in reat-
tendance rates. Kaplan-Meier survival curves were calculated
and displayed as time to ﬁrst clinical infection with the same
species over a 42-day observation period following an initial Pf
or Pv infection. All rates are displayed with a conﬁdence inter-
val (CI) of 95%.
RESULTS
General Description of the Cohort
Between June 2006 and May 2010, 1605 children aged 3–27
months were enrolled and followed up in the IPTi randomized
controlled trial (Madang = 1125 and Maprik = 480). The mor-
bidity surveillance recorded a total of 8944 illness episodes
(Madang = 5978 and Maprik = 2966), of which 7223 involved
fever (Madang = 5249, Maprik = 1974); the study ﬂowchart is
shown in Figure 1. Thirteen deaths and 371 severe illnesses
were reported during the observation period.
Of 5670 febrile episodes (Madang = 4103, Maprik = 1567),
1728 (30%, 95% CI: 29%–32%) had a positive RDT for any
species and 1682 were treated with AL. Of these, 1261 were
conﬁrmed by BS, and 152 had no BS performed and 40 had a
mixed infection with Pf and Pv. Table 1 displays the correla-
tion between positive RDT results and BS results.
Clinical Treatment Failure Rates for Pv and Pf Malaria at Days 7,
28, and 42
After excluding episodes in children who received an IPTi
dose within 42 days following treatment with AL and who had
mixed infections, 594 Pv and 332 Pf clinical malaria episodes
conﬁrmed by BS and RDT were identiﬁed. Table 2 details the
rates of reattendance following Pv and Pf malaria episodes
treated with AL. Clinical treatment failure rates, deﬁned as
BS ± RDT positive for the same species upon reattendance
within 7, 28, and 42 days, were 0.2%, 2.2%, and 12.0%, respec-
tively for Pv. Comparatively, the rates for Pf were 0.3%, 1.2%,
and 3.6%, respectively. Details of treatment failure rates for
mixed infections and reinfection with heterologous species (Pf
following a Pv infection and vice versa) are presented in Sup-
plementary Table 2.
In the survival analysis, treatment failure rate was signiﬁ-
cantly higher for Pv compared to Pf (HR, 1.79 [95% CI, 1.15–
2.76], P = .009). Kaplan-Meier survival curves with 95% CIs
showing time to ﬁrst clinical Pv and Pf clinical infections are
shown in Figure 2.
Clinical Outcome of Children Treated With AL Based on RDT
Results Within 28 Days
The outcomes up to day 28 for all children who were treated
for clinical malaria with AL based on RDT results in the out-
patient clinics are displayed in Figure 3. We observed that 178
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of 1566 infants (11.4%) reattended the clinic for an ongoing
or new fever episode; 162 were nonsevere cases. In total, 29
(1.9%) children reattended the clinic with a malaria episode
conﬁrmed by BS. Among the 16 who experienced a severe
illness, up to 3 different “on-site” diagnoses were recorded per
child. Seven were diagnosed with clinical malaria and 9 with a
lower respiratory tract infection, 8 had neurological syndromes
(such as febrile ﬁts or meningitis), 3 had anemia, and 3 had
other diagnoses. One child with a severe illness died the day
after admission, with the dual diagnosis of lower respiratory
tract infection and possible severe malaria. This child had a
severe respiratory distress syndrome on admission, and a posi-
tive RDT result but negative BS. No adverse event related to
AL was reported. About 20% of children did not undergo
blood collection while presenting with a severe illness.
Reasons included that the admission occurred after hours
when no study staff was present, the severe illness occurred at
home (particularly in cases of death), or the parents refused
the bleeding. If the observation period is extended to 42 days,
the clinical outcomes are not different.
Figure 1. Study ﬂowchart. Abbreviations: AL, artemether/lumefantrine; BS, blood slide; IPTi, intermittent preventive treatment in infancy; mix, mixed
infection; Pf, Plasmodium falciparum; Pv, Plasmodium vivax; RDT, rapid diagnostic text.
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DISCUSSION
We investigated in a large cohort of young children the effec-
tiveness in routine practice of a common treatment with arte-
mether/lumefantrine for clinical malaria due to Pf or Pv
diagnosed by RDT. We compared the rate of reattendance in
children with Pv and Pf clinical infections. The clinical re-
sponse to treatment was very good for both species, as only
1.2% and 2.2% of children who were initially diagnosed with
Pf and Pv, respectively, reattended with a BS positive for the
same species within 28 days. However, by day 42, the clinical
treatment failure rate was signiﬁcantly higher for Pv (12%)
compared to Pf (3.6%). The difference is most likely due to
relapsing Pv infections originating from hepatic hypnozoites,
which do not occur in Pf.
It should be noted that these ﬁgures do not take into con-
sideration illness episodes where only the RDT was positive
upon reattendance, as RDT results can remain positive for
several weeks after a treatment [15–17]. These data indicate
clearly that a common antimalarial treatment of AL for both
Pf and Pv provides an excellent early clinical response [2, 6].
However, while the overall effectiveness for the treatment of Pf
Table 1. Corresponding Blood Slide Results for All Children
With Positive Rapid Diagnostic Test Results Treated With
Artemether/Lumefantrine at First Attendance (N = 1682)
Non-
Pf
Pf±Mixed
Infectiona Total
BS results (research read)
Negative 110 159 269
Plasmodium falciparum 10 357 367
Plasmodium vivax 570 267 837
Pm 8 0 8
Mixed infection
(P. falciparum &
P. vivax)
3 46 49
No BS 41 111 152
Total 742 940 1682
Abbreviations: BS, blood slide; Pf, Plasmodium falciparum; Pm, Plasmodium
malariae.
a Rapid diagnostic tests have one strip common to all 4 species (phosphatase
Lactate Dehydrogenase antigen) and one specific for Pf (histidine-rich protein
II antigen). If both are positive, it is impossible to differentiate a single Pf
infection from a mixed infection (Pf ± another species).
Table 2. Crude Rates of Reattendance for Children Having a Clinical Malaria Episode Conﬁrmed by Rapid Diagnostic Test and Blood
Slide and Treated With Artemether/Lumefantrine Presenting With a New Clinical Malaria Due to the Same Species (Polymerase Chain
Reaction Uncorrected)
No. of
Malaria
Episodes
Reattendance 0–7 d
With Same Species
Reattendance 0–28 d
With Same Species
Reattendance 0–42 d With
Same Species
BS+/
RDT+
or −
BS−/
RDT+
BS−/
RDT−
No BS/
RDT
BS+/
RDT+
or −
BS−/
RDT+
BS−/
RDT−
No BS/
RDT
BS+/
RDT+
or −
BS−/
RDT+
BS−/
RDT−
No BS/
RDT
Pv 597 No. 1 2 7 10 13 3 65 15 71 14 92 22
% 0.2 0.3 1.2 1.7 2.2 0.5 10.9 2.5 12.0 2.4 15.5 3.7
Pf 332 No. 1 3 0 2 4 26 6 2 12 38 18 7
% 0.3 0.9 0.0 0.6 1.2 7.8 1.8 0.6 3.6 11.4 5.4 2.1
Included are malaria cases (defined as fever episode with positive RDT plus treatment with AL plus no positive RDT in the past 2 weeks, no fever episode in the
past 4 weeks, and no critical illness) that were confirmed by BS and did not receive any intermittent preventive treatment in the next 42 days following the initial
diagnosis of malaria. Mixed infections confirmed by both RDT and BS were excluded.
Abbreviations: BS+/RDT+ or −, definite or clinical malaria; BS−/RDT+, possible clinical malaria; BS−/RDT−, negative malaria or non-Pf/non-Pv malaria; BS, blood
slide; Pf, Plasmodium falciparum; Pv, Plasmodium vivax; RDT, rapid diagnostic test.
Figure 2. Kaplan–Meier estimates of the proportion of patients re-
maining free of clinical infection following an initial treatment with arte-
mether/lumefantrine. Children who underwent an intermittent preventive
treatment in infancy visit between day 0 and day 42 were censored at
the time they received the treatment. Abbreviations: Pf, Plasmodium fal-
ciparum; Pv, Plasmodium vivax.
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is excellent, a high rate of late clinical failure was observed for
Pv if AL was used without an antirelapse therapy.
The reattendance rates appear to be comparable than those
previously reported in PNG, Indonesia, or Africa [4, 11, 18–20].
In a study performed in PNG, a late clinical failure rate by day
42 of 15.2% was reported compared to 12% in the present
study. This small difference was expected, as the previous in
vivo efﬁcacy studies included systematic screening for both
parasitemia and signs and symptoms of febrile illness on
deﬁned days rather than spontaneous attendance such as the
present study. Passive case detection may better identify illness
episodes of signiﬁcant importance and real health-seeking
behavior, but is bound to detect fewer failures. Despite these
methodological differences, our ﬁndings conﬁrm the previous-
ly reported high late clinical failures rates with AL for Pv.
Given the low effectiveness of AL against late Pv clinical
treatment failures (>28 days), the addition of a treatment
course of an efﬁcient drug against liver stage parasites is re-
quired to improve treatment outcomes. Primaquine is current-
ly the only licensed drug for the radical cure of hypnozoites
and, given its activity against gametocytes, it would also aid in
reducing transmission [21]. Although very well tolerated in
G6PD-normal children in PNG [22], there are safety concerns
regarding routine use of primaquine because of the risk of
Figure 3. Reattendance and outcomes within 28 days of children treated with artemether/lumefantrine for a clinical malaria episode based on a
positive rapid diagnostic text result. Abbreviations: BS, blood slide; IPTi, intermittent preventive treatment in infancy; mix, mixed infection; Pf, Plasmodi-
um falciparum; Pv, Plasmodium vivax; RDT, rapid diagnostic text.
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hemolysis in G6PD-deﬁcient patients [23]. Consequently,
experts recommend systematic testing for enzyme deﬁciency
to be performed prior to treatment or, where this is not logis-
tically feasible, careful monitoring of patients and immediate
cessation of primaquine treatment at the ﬁrst sign of hemoly-
sis. Given the absence of a reliable, easy-to-use point-of-care
G6PD test, both strategies are logistically difﬁcult to imple-
ment in many countries with signiﬁcant burden of non-Pf
malaria. In the interim, an alternative may be the use of a
common treatment such as dihydroartemisinin/piperaquine
(DHA/PPQ), which provides a longer posttreatment prophy-
lactic effect for Pv infections and thus may suppress the ﬁrst
Pv relapse [24]. The standard treatment guideline in PNG,
which includes AL as common ﬁrst-line treatment for Pf and
Pv together with primaquine treatment in parasitologically
conﬁrmed Pv cases and DHA/PPQ as second-line treatment,
is therefore a rational short-term strategy.
The present work explores also the clinical outcome of fe-
verish children managed according to RDT’s results and
treated with AL when positive in a routine setting. The major-
ity of children initially diagnosed with malaria reattending the
clinic with fever within 28 days had an alternative diagnosis to
malaria and only 1.9% of all children treated with AL based
on positive RDT came back within 1 month with a BS-
conﬁrmed parasitemia. The only death that occurred following
a treatment with AL was probably related to a cause other
than malaria. Finally, no serious adverse event related to AL
was reported. These data complement previous work on RDT-
based management of malaria that showed, in the same
cohort, that withholding antimalarial drugs from children
with a negative RDT was safe in a country with a high burden
of non-Pf malaria [14].
This study was carried out alongside a passive case detec-
tion system, which leaves patients free to decide if they want
to visit a health facility when sick (or go elsewhere) and which
facility they wish to visit. A few malaria cases may have been
missed. This, however, reﬂects routine practice, as fever epi-
sodes of minor importance often cure spontaneously. Some
children may have also received over-the-counter medication,
but this is rather uncommon in PNG. Also, AL was not avail-
able in the country at the time of the study. Finally, because of
the nature of the study, adherence to treatment was not moni-
tored by the study team, except for the ﬁrst dose that was ad-
ministered by the nurse. It is therefore reassuring to observe
that even if adherence might have been suboptimal, the treat-
ment was effective enough to achieve a good initial clinical
response. This contradicts a previous report arguing that a
poor adherence to AL might challenge its effectiveness [20].
In conclusion, this study shows that a common treatment
with AL used on its own provides a good initial clinical re-
sponse but is insufﬁcient to prevent late clinical treatment
failures of Pv. Primaquine should always complement AL
when feasible, even if the effectiveness of this combination is
not yet entirely known. Therefore, new strategies that efﬁcient-
ly prevent relapses of Pv hypnozoites need to be investigated.
In the absence of better treatment and diagnostic options, the
use of AL in young children in routine practice is an accept-
able, interim option in areas highly endemic for Pf and Pv and
with a high level of parasites resistant to chloroquine. Ideally,
second-line treatment should be a long-acting ACT, combined
with rational use of primaquine.
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